Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

BACKGROUND: Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors works by reactivating immune cells. Considering the accessibility of noninvasive liquid biopsies, it is advisable to employ peripheral blood lymphocyte subsets to predict immunotherapy outcomes. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Ruixuan, Tang, Hui, You, Tingting, Xu, Xiuxiu, Li, Sijian, Li, Zepeng, Liu, Yuan, Qiu, Wei, Zhou, Na, Li, Ningning, Ge, Yuping, Guo, Fuping, Sun, Yuhong, Wang, Yingyi, Li, Taisheng, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038730/
https://www.ncbi.nlm.nih.gov/pubmed/36969245
http://dx.doi.org/10.3389/fimmu.2023.1125876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038730/
https://www.ncbi.nlm.nih.gov/pubmed/36969245
http://dx.doi.org/10.3389/fimmu.2023.1125876

Ejemplares similares